News | March 30, 2024
Aragen operationalizes first phase of its US$ 30 million Biologics manufacturing facility in India
Executes the first project for developing and manufacturing a novel anticancer mAb
Executes the first project for developing and manufacturing a novel anticancer mAb
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Subscribe To Our Newsletter & Stay Updated
